Daniel A Ollendorf

Summary

Publications

  1. pmc Toward evidence-based decisions in diagnostic radiology: a research and rating process for multiple decision-makers
    Daniel A Ollendorf
    Institute for Clinical and Economic Review, Massachusetts General Hospital, Boston, 02114, USA
    Acad Radiol 19:1049-54. 2012
  2. ncbi request reprint Impact of co-prescribed glatiramer acetate and antihistamine therapy on the likelihood of relapse among patients with multiple sclerosis
    Daniel A Ollendorf
    Institute for Clinical and Economic Review, Boston, MA, USA
    J Neurosci Nurs 40:281-90. 2008
  3. pmc The diagnostic performance of multi-slice coronary computed tomographic angiography: a systematic review
    Daniel A Ollendorf
    Institute for Clinical and Economic Review, Boston, MA, USA
    J Gen Intern Med 26:307-16. 2011
  4. doi request reprint Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population
    Daniel A Ollendorf
    IMS Health, Inc, Norwalk, Connecticut, USA
    Clin Ther 31:825-35. 2009
  5. doi request reprint Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis
    Julia H Hayes
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, Institute for Clinical and Economic Review, Institute for Technology Assessment, Boston, MA 02115, USA
    Ann Intern Med 158:853-60. 2013
  6. ncbi request reprint Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population
    Daniel A Ollendorf
    Analytic and Consulting Services, PharMetrics, Inc, Watertown, Massachusetts, USA
    Am J Manag Care 8:S203-13. 2002
  7. pmc Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study
    Thomas D Gilbert
    Market Research, The Ipsen Group, Inc, 27 Maple Street, Milford, MA 01757, USA
    BMC Musculoskelet Disord 5:36. 2004
  8. ncbi request reprint Biomarker tests for the diagnosis of Alzheimer's disease: Generating evidence to inform insurance coverage determinations
    Steven D Pearson
    The Institute for Clinical and Economic Review, Massachusetts General Hospital s Institute for Technology Assessment, Boston, MA, USA Electronic address
    Alzheimers Dement 9:745-52. 2013
  9. ncbi request reprint Effect of initial ziprasidone dose on length of therapy in schizophrenia
    Amie T Joyce
    PharMetrics, Inc, 311 Arsenal Street, Watertown, MA 02472, USA
    Schizophr Res 83:285-92. 2006
  10. ncbi request reprint End-stage renal disease-associated managed care costs among patients with and without diabetes
    Amie T Joyce
    Senior Research Consultant, PharMetrics, Inc, 311 Arsenal St, Watertown, MA 02472, USA
    Diabetes Care 27:2829-35. 2004

Detail Information

Publications19

  1. pmc Toward evidence-based decisions in diagnostic radiology: a research and rating process for multiple decision-makers
    Daniel A Ollendorf
    Institute for Clinical and Economic Review, Massachusetts General Hospital, Boston, 02114, USA
    Acad Radiol 19:1049-54. 2012
    ..The issues raised, controversies considered, and use of the ratings in setting policy are discussed in relation to each example...
  2. ncbi request reprint Impact of co-prescribed glatiramer acetate and antihistamine therapy on the likelihood of relapse among patients with multiple sclerosis
    Daniel A Ollendorf
    Institute for Clinical and Economic Review, Boston, MA, USA
    J Neurosci Nurs 40:281-90. 2008
    ..962, 95% CI = 0.675, 1.373). In conclusion, our findings indicate that concomitant use of prescription AHs with GA therapy does not appear to significantly affect the risk of relapse among patients with multiple sclerosis...
  3. pmc The diagnostic performance of multi-slice coronary computed tomographic angiography: a systematic review
    Daniel A Ollendorf
    Institute for Clinical and Economic Review, Boston, MA, USA
    J Gen Intern Med 26:307-16. 2011
    ....
  4. doi request reprint Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population
    Daniel A Ollendorf
    IMS Health, Inc, Norwalk, Connecticut, USA
    Clin Ther 31:825-35. 2009
    ..Tumor necrosis factor (TNF) antagonists are commonly used to treat rheumatoid arthritis (RA). Differences in the dosage and mode of administration of these agents may result in differential rates of dosage adjustment and costs of care...
  5. doi request reprint Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis
    Julia H Hayes
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, Institute for Clinical and Economic Review, Institute for Technology Assessment, Boston, MA 02115, USA
    Ann Intern Med 158:853-60. 2013
    ..Observation is underutilized among men with localized, low-risk prostate cancer...
  6. ncbi request reprint Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population
    Daniel A Ollendorf
    Analytic and Consulting Services, PharMetrics, Inc, Watertown, Massachusetts, USA
    Am J Manag Care 8:S203-13. 2002
    ..To compare the impact of leflunomide on resource utilization and costs relative to that of etanercept and infliximab among patients with rheumatoid arthritis (RA) in a managed care setting...
  7. pmc Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study
    Thomas D Gilbert
    Market Research, The Ipsen Group, Inc, 27 Maple Street, Milford, MA 01757, USA
    BMC Musculoskelet Disord 5:36. 2004
    ..We examined dosing and costs among RA patients newly treated with infliximab or etanercept under conditions of typical clinical practice...
  8. ncbi request reprint Biomarker tests for the diagnosis of Alzheimer's disease: Generating evidence to inform insurance coverage determinations
    Steven D Pearson
    The Institute for Clinical and Economic Review, Massachusetts General Hospital s Institute for Technology Assessment, Boston, MA, USA Electronic address
    Alzheimers Dement 9:745-52. 2013
    ..Corresponding research recommendations are also included, framed to serve as a guide for future AD diagnostics research. ..
  9. ncbi request reprint Effect of initial ziprasidone dose on length of therapy in schizophrenia
    Amie T Joyce
    PharMetrics, Inc, 311 Arsenal Street, Watertown, MA 02472, USA
    Schizophr Res 83:285-92. 2006
    ..To examine the effects of initial ziprasidone dose on discontinuation rates, using retrospective integrated medical and pharmacy claims data...
  10. ncbi request reprint End-stage renal disease-associated managed care costs among patients with and without diabetes
    Amie T Joyce
    Senior Research Consultant, PharMetrics, Inc, 311 Arsenal St, Watertown, MA 02472, USA
    Diabetes Care 27:2829-35. 2004
    ..To examine the direct costs of care before and after onset of end-stage renal disease (ESRD) for patients with and without diabetes based on analyses of retrospective healthcare claims data...
  11. pmc Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis
    Julia H Hayes
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    JAMA 304:2373-80. 2010
    ..Treatment of these cancers is associated with substantial morbidity. Active surveillance is an alternative to initial treatment, but long-term outcomes and effect on quality of life have not been well characterized...
  12. doi request reprint Management options for children with attention-deficit/hyperactivity disorder: a regional perspective on value
    Daniel A Ollendorf
    Institute for Clinical and Economic Review, MGH Institute for Technology Assessment, 101 Merrimac Street, 10th Floor, Boston, MA 02114, USA
    J Comp Eff Res 2:261-71. 2013
    ..This article summarizes the deliberations and reflects on lessons learned regarding use of region-specific economic analyses to guide decision-making. ..
  13. doi request reprint An integrated evidence rating to frame comparative effectiveness assessments for decision makers
    Daniel A Ollendorf
    Institute for Clinical and Economic Review ICER, Massachusetts General Hospital Institute for Technology Assessment, Boston, MA 02114, USA
    Med Care 48:S145-52. 2010
    ....
  14. doi request reprint A simulation model of clinical and economic outcomes of cardiac CT triage of patients with acute chest pain in the emergency department
    Alexander Goehler
    Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, 101 Merrimac St, 10th Fl, Boston, MA 02114, USA
    AJR Am J Roentgenol 196:853-61. 2011
    ..Our objective was to construct a simulation model to estimate clinical and economic outcomes...
  15. ncbi request reprint Burden of illness among commercially insured patients with Alzheimer's disease
    Amie T Joyce
    PharMetrics Inc a unit of IMS, Watertown, MA, USA
    Alzheimers Dement 3:204-10. 2007
    ..CONCLUSIONS: The annual economic burden of AD to third-party payers is more substantial than previously estimated ($3,805 to $8,200)...
  16. ncbi request reprint An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia
    Libby Black
    PharMetrics, Inc, 311 Arsenal Street, Watertown, MA 02472, USA
    Am J Manag Care 12:S99-S110. 2006
    ..To examine utilization and costs of care for benign prostatic hyperplasia (BPH)-related services in a large cohort of commercially insured persons...
  17. doi request reprint Through the looking glass: making the design and output of economic models useful for setting medical policy
    Daniel A Ollendorf
    Institute for Clinical and Economic Review, One State Street, Suite 1050, Boston, MA 02109, USA
    J Comp Eff Res 3:53-61. 2014
    ..We conclude with a series of recommendations for effective presentation of economic models to US policy-makers. ..
  18. doi request reprint Management strategies for attention-deficit/hyperactivity disorder: a regional deliberation on the evidence
    Sarah K Emond
    Institute for Clinical and Economic Review, MGH Institute for Technology Assessment, Boston, MA 02114, USA
    Postgrad Med 124:58-68. 2012
    ..The ADHD CEPAC meeting demonstrated the important role that a public, transparent deliberation on the latest medical evidence can have in supporting informed decision making and efficient use of health care resources...
  19. pmc Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia
    Daniel A Ollendorf
    Analytic and Consulting Services, PharMetrics, Inc, Watertown, Massachusetts, USA
    MedGenMed 6:5. 2004
    ..Understanding the association between use of antipsychotics and onset of diabetes...